Canterbury DHB
When treated using standard chemotherapy and autografts, myeloma has a median survival of about 4 years. The use of newer drugs such as thalidomide, bortezomib and lenalidomide has probably increased the median survival but still does not cure the disease.
Opinions differ as to whether allogeneic transplant offers a cure for myeloma, but long term disease-free complete molecular remissions are well documented using this approach.
There are many identified markers that can predict for poor prognosis. One of the most simple, powerful and clinically relevant is from Greipp et al – the International Staging System for myeloma:
STAGE |
B-2-microglobulin |
Albumin |
Median Survival(months) |
||
1 |
<3.5 mg/l |
>35 g/l |
62 |
||
11 |
Neither stage 1 nor stage 111 |
45 |
|||
111 |
>5.5 mg/l |
Any |
29 |
Renal failure at presentation carries with it a median survival of 8 months.
Topic Code: 5584